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Is revisional surgery mandatory when an
unexpected sarcoma diagnosis is made
following primary surgery?
Georgios Koulaxouzidis1*, Eugenia Schwarzkopf1, Holger Bannasch1,2 and G. Björn Stark1
Abstract
Background: Soft tissue sarcomas (STS) are often diagnosed unexpectedly after surgery, and many excisions are
incomplete. As histopathological assessments are challenging, patients later referred to comprehensive cancer
centers (CCC) often come with an unclear status. This can make treatment planning problematic. We investigated
the reliability of primary histopathological assessments, whether revisional surgery improved resection status, and
the prognostic value of residual tumor at re-excision.
Methods: We analyzed the demographic and clinical characteristics of all patients referred to our CCC between 2003
and 2013. We compared patients treated exclusively at our CCC with those who had primary surgery elsewhere, and
focused on resection margins, re-excision type, residual tumor, resection status after re-excision, and oncological
outcome.
Results: Over half (n = 110) of all patients (n = 204) were referred from elsewhere. Seventy-one had undergone an
excision without suspicion of malignancy. Resection status in referred patients was significantly inferior to the CCC
group (p < 0.0001), although the latter had significantly more serious tumors and advanced disease stages (p < 0.05).
The residual tumor rate was 53.13 %, with a significantly higher probability in an upper extremity (p = 0.001). Initial
histopathological classification was misleading in 46.9 % of cases. Re-excision improved resection status in 69 % of
cases. Residual tumor presumably leads to higher rates of local recurrence (p = 0.057) and significantly shorter times to
recurrence (p < 0.05).
Conclusions: Re-excision should always follow unplanned STS excisions. Resection margins and histopathological
assessments from referring institutions are often unreliable and unsuitable for treatment planning. Residual tumor is a
risk factor for earlier and more likely local recurrence.
Keywords: Soft tissue sarcoma, Unplanned excision, Re-excision, Revisional surgery, Whoops procedure,
Comprehensive cancer center
Background
It is generally recommended that soft tissue sarcomas
(STS) should be treated in tumor centers [1–8]. Ideally, a
patient should be referred to a tumor center when a sar-
coma is suspected and before undergoing a biopsy or exci-
sion [9]. It is essential that a meticulous diagnostic and
staging workup is performed and that a multidisciplinary
tumor board draws up a treatment plan and considers a
range of reconstructive surgeries [9–11].
However, soft tissue sarcomas are a heterogeneous group
of rare malignant mesenchymal tumors with an annual
incidence of two to three per 100,000 cases [12, 13]. It is
estimated that every 200 to 300 lumps is a sarcoma. Given
the rarity and diversity of these tumors, it is not surprising
that excisions are often done without the preoperative sus-
picion of a malignant tumor, without appropriate preopera-
tive imaging, without a sufficient biopsy or staging, and
without regard for adequate resection margins. Such pro-
cedures are known as unplanned excisions [4, 14] or
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“whoops” procedures [2]. Radical tumor extirpation is
the cornerstone of treatment [15, 16]. No other adju-
vant or neo-adjuvant treatment provides adequate local
tumor control [17]. Unplanned excisions are often in-
complete, with residual tumor reported in 35 to 74 % of
patients [3, 4, 14, 18–21]. These cases are associated
with more mutilating surgery and higher treatment
costs [6, 22]. Data on how re-excision affects onco-
logical outcomes are conflicting. Principally, adequate
re-excision has been said to improve local and systemic
tumor control, or even overall survival, compared to
single adequate primary tumor excision [23, 24]. Other
studies, however, have shown higher local recurrence
rates, impaired prognosis and increased rates of metas-
tasis even after sufficient re-excision [3, 6, 25, 26].
Although re-excision is generally recommended [3, 4,
16, 18], clinical or radiological suspicion of residual
tumor is rare and patients receive advice based on the
treatment given and on the existing histopathological
information. Reliable histopathological assessments of
excised tissue or biopsy specimens suspected of sarcoma
require a pathologist who has experience in that par-
ticular field. Therefore, even in comprehensive cancer
centers (CCCs) like ours, which specializes in sarcoma
treatment, external experts are regularly tasked with
reference reviewing histopathological assessments. Pre-
viously published data show that the reliability of histo-
pathological assessments performed by inexperienced
pathologists is often questionable [27–29]. Initial tumor
characteristics, such as size, location, and grading, as
well as preoperative and postoperative radiation were
found to be of no help in predicting the probability of a
patient having residual tumor after an unplanned exci-
sion [4]. Additionally, cross-sectional imaging such as
MRI does not predict residual tumor with sufficient
sensitivity and specificity [30].
In our study, we evaluated the reliability of primary
histopathological assessments produced after unplanned
excisions that were performed in a non-CCC setting.
Additionally, we assessed the improvement of the resec-
tion status by revisional surgery. Finally, we highlighted
the prognostic value of residual tumor at re-excision for
local and systemic tumor control.
Methods
A retrospective chart review was performed for all pa-
tients who were referred to our center for definitive
treatment of STS. Particular attention was paid to
patients who had undergone a primary excision in a
non-CCC setting. Patients treated between 1 January
2003 and 31 December 2013 were included. The follow-
up period was extended until 30 April 2014. Only pa-
tients with complete data sets were included.
Presentation status at referral and resection status
Patients who had previously undergone surgery were
categorized according to their status at presentation:
(a) Patients referred after an unplanned excision
(“whoops” procedure)
(b) Patients referred with local recurrence after a single
excision or repeated excision
(c) Patients referred after an incisional biopsy
Staging was performed according to the previous sta-
ging procedures and in line with the guidelines of our
CCC. All patients underwent re-excision after their cases
were presented to the multidisciplinary tumor board of
our CCC. An individual therapy plan was drawn up at a
second presentation to the board, with definitive histo-
pathological assessment after re-excision.
The following data were collected: gender, age at diag-
nosis, location (extremity, trunk), size (<5 cm, ≥5 cm),
depth (superficial or deep to the fascia), histotype, grade
(FNCLCC grading), presentation status at referral, and
primary resection margins (R0, R1, or R2 resection).
Resection status at referral and after re-excision was
compared to the resection status achieved in patients
treated exclusively in our center.
Residual tumor
After re-excision, a histopathological assessment was
performed. If residual disease was found, we determined
the improvement of resection status by re-excision.
Characteristics of cases with and without residual tumor
were assessed after patient categorization according to
the resection status and tumor detection. Each patient
was coded in terms of his or her primary resection sta-
tus (R0, R1, or R2, external pathology), the resection sta-
tus after re-excision (R0, R1, R2, CCC pathology with
external expert review in individual cases), and the pres-
ence or absence of residual tumor at re-excision (0: no
residual tumor found; 1: residual tumor found). For
example, R1-R0-1 means that the patient was referred
for definitive treatment after microscopic incomplete
resection (R1 resection), that a complete resection (R0)
was achieved after re-excision, and that residual tumor
was found in the histopathological workup of the re-
excision specimen. The surgical techniques used for the
re-excision were also analyzed. For the referred patients,
we determined the progression-free survival with regard
to local recurrence and metastasis, and the disease-
specific survival, based on the presence or absence of
residual tumor.
Local and systemic tumor control
Significance of local tumor recurrence based on residual
tumor at re-excision was estimated with a Chi2 test. All
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groups were compared using a univariate test for rele-
vant group characteristics and prognostic factors (gen-
der, age, tumor grade, tumor size, tumor location,
diagnosis, therapy). Dates of neoplastic events (local
recurrence, distant metastasis) and survival status (alive
with disease, AWD; no evidence of disease, NED; death
from other causes, DOC; and died of disease, DOD) and
dates of death and last follow-up were assessed.
Statistics
For the statistical analysis of the categorical data, we
used either a Chi2 test or Fisher’s exact test, depending
on the number of cases compared. All groups and prog-
nostic factors (gender, age, tumor grade, tumor size,
tumor location, diagnosis, therapy) were analyzed by
univariate analysis. Survival analysis data were presented
as Kaplan–Meier curves. Comparison was done by log-
rank test. A two-sided p value of <0.05 was assumed as
significant.
Results
From 1 January 2003 to 31 December 2013, 204 patients
underwent surgery for STS at our plastic surgery insti-
tute. Of those, 110 patients (53.9 %) were referred to us
after receiving therapy elsewhere.
Presentation status at referral
Presentation status was established with certainty in 96
cases (87.3 %). A “whoops” procedure was performed in
71 cases (74 %). Recurrent local disease, either after a
single excision or repeated excision, was found in 22
cases (22.9 %). Just three cases (3.1 %) were presented
after incisional biopsy.
Resection status
Histopathological findings for the 71 patients who
were referred to us after an unplanned excision and
who had complete presentation status showed that
16.7 % had complete tumor resection (R0 resection
status), 69.8 % had microscopic incomplete resection
(R1 resection status), and 13.5 % had macroscopic in-
complete resection (R2 resection status). By contrast,
the data for patients treated exclusively at our institute
showed that, after primary tumor excision, 83 % had
complete tumor resection, 13.8 % had microscopic
incomplete resection, and 3.2 % had macroscopic
incomplete resection (n = 94) (Fig. 1).
Comparing both groups reveals several notable dif-
ferences (Table 1). Tumors treated exclusively at our
institution were more often high-grade tumors (Chi2
test, p = 0.019), larger than 5 cm (Chi2 test, p < 0.001),
Fig. 1 Resection status. Resection status was defined as complete resection (R0 resection), microscopic residual tumor (R1 resection), and macroscopic
incomplete resection (R2 resection). It is displayed on the x-axis. Of the patients referred for definitive treatment with complete data sets (n = 96),
16.7 % had R0 resection status, 69.8 % had R1 resection status, and 13.5 % had R2 resection status. By contrast, of the patients who underwent primary
excision at our institute (n = 94), 83 % had R0 resection status, 13.8 % had R1 resection status, and 3.2 % had R2 resection status. The resection status of
referred patients at presentation was significantly inferior to that of patients treated exclusively at our CCC (Chi2 test, p < 0.0001). After re-excision,
93.8 % of the referred patients had R0 resection status and 6.3 % had R1 resection status
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and had a higher National Comprehensive Cancer
Network (NCCN) stage (Chi2 test, p < 0.001). However,
there was no difference in the incidence of histological
diagnosis (Chi2 test, p = 0.127). Although larger and
higher-grade tumors were treated exclusively at our
institute, the number of successful primary excisions
was significantly higher (Chi2 test, p < 0.0001). For
those who were initially treated elsewhere and had
their resection status redefined after re-excision, the
results were comparable to the group who were treated
exclusively at our institute: we found complete resec-
tion in 93.8 % of cases, microscopic incomplete resec-
tion in 6.3 % of cases, and no cases of macroscopic
incomplete resection (Fig. 1). Resection status was
improved in 69 % of cases.
Residual tumor
Histopathological evidence of residual tumor after re-
excision was found in 38 (53.5 %) of the referred
patients who had undergone a “whoops” procedure
(n = 71). As mentioned above, cases were coded ac-
cording to their primary resection status—resection
status after re-excision—and the existence of residual
tumor at re-excision.
Our investigations of the reliability of primary resection
status showed that half of the cases referred to us with
Table 1 Demographic and clinical data of referred patients and patients treated exclusively at our CCC
CCC patients (n=94) Referred patients with unplanned excision (n=71) p-value Statistical test
Demographics Students t test
Male 47.9% 53.1% 0.469
Female 52.1% 46.9%
Under 50 years of age 27.7% 33.3% 0.396
50 years of age and older 72.3% 66.7%
Median age 59.49 55.94 0.156
Clinical data
FNCLCC grade Chi2 test
Low 23.0% 23.5% 0.019
Intermidiate 21.8% 40.0%
High 55.2% 36.5%
Tumour size Chi2 test
Size ≤ 5 cm (T1) 30.2% 51.8% <0.001
Size > 5 cm (T2) 62.4% 48.2%
Tumour location with regard to fascia Chi2 test
Superficial (Ta) 32.2% 34.1% 0.788
Deep (Tb) 67.8% 65.9%
NCCN stage Chi2 test






Histopathological diagnosis Chi2 test
Liposarcoma 27.4% 37.3% 0.127
Leiomyosarcoma 4.8% 4.8%
Rhabdomyosarcoma 2.4% 3.6%
Synovial sarcoma 4.8% 4.8%
Malignant fibrous histiocytoma 33.3% 21.7%
Fibrosarcoma 8.3% 13.3%
Other 19.0% 14.5%
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supposed complete tumor resection showed evidence of
residual tumor after revisional surgery (R0-R0-1, n = 6).
On the other hand, no evidence of residual tumor was
found in 27 cases that were initially said to have residual
tumor (R1-R0-0 n = 25; R2-R0-0 n = 2). Primary histo-
pathological resection status was thus misleading in nearly
half of the referred cases (n = 33, 46.5 %). The six cases that
presented with complete tumor resection but showed
residual tumor in revisional surgery (R0-R0-1) very clearly
demonstrate the potentially disastrous consequences of a
misleading histopathological assessment. However, in the
other 27 cases, revisional surgery allowed an ostensible
revision of resection status and prevented adjuvant
overtreatment.
On the other hand, revisional surgery that excised the
residual tumor led to a real improvement in resection
status in half of the cases (n = 35, 49.3 %; R0-R0-1 n = 6,
R1-R0-1 n = 22, R2-R0-1 n = 6, and R2-R1-1 n = 1). The
surgery truly improved local tumor control in these
cases. The results definitely support a liberal indication
for revisional surgery in cases of unplanned sarcoma
excision.
In some cases, revisional surgery did not improve
resection status (R0-R0-0 n = 6, R1-R1-1 n = 3,
12.7 %) (Fig. 2). Our revisional surgery involved per-
forming a simple re-excision with the aim of achiev-
ing a safety margin (n = 19), a wide excision (n = 41),
a compartment resection (n = 7), a major amputation
(n = 2), and a marginal excision (n = 2). We found that
primary tumors located in an upper extremity were
an independent risk factor for residual tumor (p =
0.001) (Table 2).
Local and systemic tumor control
Residual tumor might be a risk factor for local recur-
rence as it approaches significance (15.63 % when
residual tumor found vs. 6.25 % when no residual tumor
found; p = 0.057; Chi2 test; Fig. 3). At the same time,
progression-free survival was significantly reduced in
cases of residual tumor (5 years of progression-free sur-
vival: 83 ± 6 % vs. 63 ± 8 %; log-rank test; p < 0.05). The
rate of metastasis was comparable (10.4 vs. 4.2 %; log-
rank test; p = 0.138) without significant difference in
metastasis-free survival (90 ± 4.5 % vs. 76.6 ± 6.7 % at
5 years; log-rank test; p = 0.127) or in disease-specific
survival (92.9 ± 3.9 % vs. 81.4 ± 6.1 % at 5 years; log-rank
test; p = 0.137; Fig. 4).
Discussion
Our CCC serves as a referral center for soft tissue sarco-
mas. Of the patients treated here, more than one in two
were referred to us after undergoing primary surgery in
a non-CCC setting. Nearly three-quarters underwent a
“whoops” procedure. This experience is consistent with
Fig. 2 Distribution of referred patients after coding. Referred patients were categorized using the following code: 1. Primary resection status: R0,
R1, or R2. 2. Resection status after re-excision: R0, R1, or R2. 3. Presence or absence of tumor at re-excision: 0 = no tumor found; 1 = tumor found.
Overall, residual tumor after re-excision was found in 53.13 % of cases. Of all the patients referred with histopathological information indicating
complete tumor resection, half had residual tumor in the re-excision specimen. In 33 cases (46.5 %), the primary histopathological information on
resection status was misleading and either overestimated or underestimated the resection margins (R1-R0-0; R2-R0-0; R0-R0-1). In 27 cases (38 %),
revisional surgery ostensibly improved resection status (R1-R0-0; R2-R0-0). In 35 cases (49.3 %), there was a real improvement (R0-R0-1; R1-R0-1;
R2-R0-1; R2-R1-1). In nine cases (12.7 %), our surgery did not improve the resection status (R0-R0-0; R1-R1-1)
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that of other authors [1, 2, 31–33]. The situation is
caused by the rarity of this heterogeneous group of
malignant mesenchymal tumors and by the fact that they
can occur anywhere in the body [12, 13, 34, 35]. Further-
more, their clinical behavior is characterized by slow
growth, they cause few physical complaints at first and
they can appear harmless in cross-sectional imagi-
ng—all of which can be misleading [36]. Certain ana-
tomical regions can pose a particular challenge. This is
the case with uterine sarcomas, for instance. They are
very rare, the symptoms are misleading, and the lack of
pathognomonic clinical or diagnostic signs means that
Table 2 Demographic and clinical data of referred patients with and without residual tumour at re-excision
Referred patients without residual
tumour (n=33)
Referred patients with residual
tumour (n=38)
p-value Statistical test
Demographics Students t test
Male 57.8% 49.0% 0.391
Female 42.2% 51.0%
Under 50 years of age 75.6% 58.8% 0.083
50 years of age and older 24.4% 41.2%
Median age 57.24 54.78 0.523
Clinical data
FNCLCC grade Chi2 test
Low 29.3% 18.2% 0.483
Intermediate 36.6% 43.2%
High 34.1% 38.6%
Tumour size Chi2 test
Size ≤ 5 cm (T1) 48.8% 54.5% 0.595
Size > 5 cm (T2) 51.2% 45.5%
Tumour location with reference to fascia Chi2 test
Superficial (Ta) 39.0% 29.5% 0.357
Deep (Tb) 61.0% 70.5%
NCCN stage Chi2 test






Histopathological diagnosis Chi2 test
Liposarcoma 37.8% 27.5% 0.861
Leiomyosarcoma 6.7% 7.8%
Rhabdomyosarcoma 2.2% 3.9%
Synovial sarcoma 6.7% 7.8%




Upper extremity 17.8% 41.2% 0.001
Lower extremity 62.2% 33.3%
Head and neck 8.9% 0.0%
Trunk 11.1% 25.5%
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delayed therapy is the rule [37]. Soft tissue sarcomas
are underestimated at different stages of treatment. An
insufficient diagnostic and staging workup, including
biopsy type and execution, could have fatal conse-
quences. A lack of experience in specific treatment or
plastic surgical reconstruction techniques can lead to
insufficient primary tumor excision and disastrous con-
sequences [3, 4, 14, 18–21, 38].
Our data clearly show that, when an unplanned sar-
coma excision is performed in a non-CCC setting, the
initial histopathological assessments are misleading and
should not be used as a basis for consultations and treat-
ment planning. In half of the cases, initial and final
resection statuses were conflicting and in some instances
resulted in mutilating surgery that may not have been
necessary. Histopathological assessments of sarcomas
are complex and challenging. Reliability depends on
experience and an institute’s caseload [27, 28, 39].
Higher caseloads at CCCs and regular reviews of histo-
pathological assessments by external experts enhance
reliability. However, a lack of sufficient number of cases
for statistical evaluation (2 out of 94) meant that we
could not compare the reliability of histopathological re-
sults after revisional surgery in patients treated exclu-
sively at our center and those treated out of a CCC.
Furthermore, the conclusions drawn from our results
are limited by the fact that the patients who were re-
ferred to our center for further treatment were pre-
selected. It is likely that many patients who supposedly
had complete tumor resection were not referred for fur-
ther treatment or re-assessment.
A primary tumor located in an upper extremity is an
individual risk factor for residual tumor. This is not sur-
prising, as the close anatomical relationship between
functionally relevant structures reduces the likelihood of
radicality during an unplanned excision. A lack of
expertise in reconstructive surgery and defect coverage
is another factor that often causes uncertainty and re-
straint in unplanned excisions.
This uncertainty and restraint is also indirectly
reflected in the radicality achieved in our center, where
revisional surgery improved the resection status in 69 %
of the referred cases. Radicality can be increased in an
interdisciplinary setting where surgeons have experience
of reconstruction. Although the patients who were
treated exclusively at our center had significantly more
high-grade and larger tumors at a more advanced
NCCN stage, the radicalism achieved was initially super-
ior and comparable after revisional surgery.
Residual tumor seems to be a prognostic factor for sig-
nificantly earlier local tumor recurrence and shows a
tendency towards an increased risk of local recurrence.
Our results are in line with Gustafson et al., who showed
that the number of operations required and the local
recurrence rate was higher in referred patients and in
patients who did not receive any treatment in a CCC
[32]. Furthermore, Kang et al. identified the level of the
referring hospital as a risk factor for oncological out-
comes [38].
However, our results conflict with the results of other
studies that show sufficient local tumor control but an
increased rate of metastasis after adequate re-excision
Fig. 3 Local recurrence rate. We compared the local recurrence rate of the referred patients based on the presence or absence of residual tumor
at re-excision (Chi2 test). The local recurrence rate after re-excision of residual tumor was 15.63 % (11 cases), compared to 6.25 % (4 cases) when
no residual tumor was found. Although the difference was not significant, there was a strong tendency towards significance (p = 0.057)
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[16, 25]. Lewis et al. published surprising data that indi-
cated that additional wide resection after an unplanned
excision was an independent, favorable variable that
improved overall survival compared to primary tumor
excision at their cancer center [24]. Other studies
showed an increased local recurrence rate and metasta-
sis rate even after re-excision [6, 18, 26]. Morii et al.
found that additional wide resection is the only therapy
option that improves oncological outcomes [23]. How-
ever, delayed re-excision seems to have no influence on
oncological outcomes [40].
In this study, we performed a retrospective chart
review, a study design in which research questions are
answered by analyzing pre-coded, patient-centered data.
The design has several drawbacks compared to prospect-
ive studies. Firstly, there is often a failure to formulate a
well-defined, clearly articulated research question before
the chart review begins. Relevant answerable questions
are often limited by the quality and amount of pre-
coded data. Secondly, operationalization of the data
and standardization of data abstraction is limited,
which means accuracy and consistency are also limited.
Fig. 4 Progression-free survival and disease-specific overall survival. We compared the referred patients based on the presence or absence of
residual tumor at re-excision. We did so using a log-rank test for the following items: a Recurrence-free survival: Time was significantly shorter in
cases where residual tumor existed (p < 0.05). [Five-year recurrence-free survival (±standard error): 83 ± 6 % without residual tumor at re-excision;
63 ± 8 % with residual tumor]. b Metastasis-free survival: No significant difference (p = 0.127). [Five-year metastasis-free survival (±standard
error): 90 ± 4.5 % without residual tumor at re-excision; 76.6 ± 6.7 % with residual tumor]. c Disease-specific overall survival: Groups were
comparable (p = 0.137). [Five-year disease-specific survival (±standard error): 92.9 ± 3.9 % without residual tumor at re-excision; 81.4 ± 6.1 %
with residual tumor]
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Thirdly, the person doing the abstraction is generally
not blinded to the hypothesis and the cases, which
leads to a reviewer bias. Notwithstanding these limita-
tions, retrospective case studies are a relevant study de-
sign for producing information on rare diseases. In the
case of such a heterogeneous and rare disease as soft
tissue sarcomas, the only way to plan and successfully
perform a prospective study is via a multicenter design.
Conclusions
An unplanned excision of a soft tissue sarcoma should
always be followed by re-excision. Resection margins
and histopathological assessments performed by low-
volume hospitals are unreliable and should not be taken
as the basis for treatment planning. Excisions performed
at high-volume centers are more radical than those done
at referring centers. Residual tumor at re-excision is a
risk factor for earlier and more likely local recurrence.
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